Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: GLP-1RA, Insulin Delivery, Other, Topics Oct 10 | 2025Ypsomed Builds US Manufacturing Site; Eccogene Eyes Hong Kong IPO; Former Novo CEO Joins Healthcare DenmarkPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 09 | 2025Novo Acquires Akero for EFX in MASHPurchase Blast
$599
Posted in: Dual/triple agonist, Insulin Delivery, Other, Topics Oct 07 | 2025Biomea Ph2 T2DM Results; AZ Ph3 Baxdrostat Data; Ionis 2025 Innovation Day; New Hanmi Ph2 Triple Agonist Study; MannKind Completes scPharmaceuticals Acquisition; Fractyl Health Preclinical Gene Therapy Data Purchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, Topics Oct 07 | 2025Ed Cinca Rejoins Novo as SVP of US Marketing; Skye’s CB1 Ph2a Dose Suboptimal; Amgen Launches its DTP Program; Wegovy Pill Available DTP via Telehealth; Costco Sells Ozempic and Wegovy; Libre Featured on ESPN; Lilly Partners with Local Manufacturers in IndiaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 02 | 2025New Orforglipron SUI Trial; Amgen VESALIUS-CV Results; EASO Recommends GLP-1RAsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 01 | 2025Alnylam/Roche Initiate Zilebesiran CVOT; Hanmi Files Obesity IND; Sagimet Ph1 MASH StudyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 30 | 2025Metsera Ph2b VESPER Results; NovoCare Partners with LifeMD; Novo Terminates CV Partnership; MindRank Ph1b Obesity Results; Cascade Initiates Ph2 MASH StudyPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucose Monitoring, Insulin Delivery, Other, Topics Sep 29 | 2025Novo Resubmits Icodec BLA; BI and Novartis Launch DTP Platforms; t:slim X2 + Control-IQ+ Now Compatible with LyumjevPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Other, SGLT2i, Topics Sep 26 | 2025AZ Launches DTP Platform; Biolinq Shine Receives De Novo Classification; Amgen Expands US Manufacturing; Fractyl REMAIN-1 Results; Sanofi Expands Insulin SavingsPurchase Blast
$599
Posted in: Autologous, Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Sep 24 | 2025Medtronic Launches Instinct CGM; SAB BIO Initiates Pivotal Ph2b T1DM Study; Lilly Terminates Ph2 Bimagrumab Study; Glooko Acquires Monarch MedicalPurchase Blast
$599
Posted in: Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Topics Sep 23 | 2025Lilly’s $6.5B Orforglipron Manufacturing Site; Novo Registers Ph2 Study of Triple Agonist; Ascletis Pharma Ph1 Results; Veru Progresses Enobosarm to Ph2b; FDA Delays T1DM Sota Decision; New O5 DTC Ad During NFL Sunday Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 22 | 2025Roche Pharma Day 2025Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 22 | 2025Pfizer Acquires Metsera in $7.3B deal; Clive Meanwell Strikes Gold…Again Purchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other, Topics Sep 19 | 2025EASD 2025 Key Press Releases (September 19) Purchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Sep 18 | 2025EASD 2025 Key Press Releases (September 18)Purchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other, Topics Sep 18 | 2025Novo EASD 2025 R&D EventPurchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 17 | 2025EASD 2025 Key Press Releases (September 17)Purchase Blast$599
Posted in: GLP-1RA, Glucose Monitoring, Other, Topics Sep 17 | 2025EASD 2025 Key Press Releases (September 16) Purchase Blast$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other, Topics Sep 15 | 2025EASD 2025 Key Press Releases (September 15) Purchase Blast
$599
Posted in: Autologous, GLP-1RA, Other, Topics Sep 12 | 2025MIRA Acquires SKNY for CB1 Asset; Structure Initiates Ph2 Body Composition StudyPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
